CEL-SCI Corporation (CVM)

US — Healthcare Sector
Peers: CTIC  AGEN  AEZS  CYCC  BCRX 

Automate Your Wheel Strategy on CVM

With Tiblio's Option Bot, you can configure your own wheel strategy including CVM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol CVM
  • Rev/Share 0.0
  • Book/Share 94.6042
  • PB 0.0251
  • Debt/Equity 1.3168
  • CurrentRatio 0.5497
  • ROIC -0.001

 

  • MktCap 12169997.0
  • FreeCF/Share -0.2142
  • PFCF -0.6722
  • PE -9.9985
  • Debt/Assets 0.4829
  • DivYield 0
  • ROE -0.01

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 5
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

CEL-SCI Announces Pricing of Public Offering
CVM
Published: May 21, 2025 by: Business Wire
Sentiment: Neutral

VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces pricing of public offering.

Read More
image for news CEL-SCI Announces Pricing of Public Offering
CEL-SCI's Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia
CVM
Published: May 21, 2025 by: Business Wire
Sentiment: Neutral

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI'S Multikine investigational cancer medicine potentially available for commercialization by summer 2025 in Saudi Arabia.

Read More
image for news CEL-SCI's Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia
CEL-SCI Announces Combination of Common Stock
CVM
Published: May 19, 2025 by: Business Wire
Sentiment: Neutral

VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces combination of common stock.

Read More
image for news CEL-SCI Announces Combination of Common Stock
CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial
CVM
Published: February 20, 2025 by: Business Wire
Sentiment: Neutral

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI to initiate Multikine Confirmatory Phase 3 Cancer Trial.

Read More
image for news CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial

About CEL-SCI Corporation (CVM)

  • IPO Date 1983-12-08
  • Website https://cel-sci.com
  • Industry Biotechnology
  • CEO Mr. Geert R. Kersten Esq.
  • Employees 43
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.